IFM Investors Pty Ltd boosted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 40.7% during the third quarter, Holdings Channel reports. The institutional investor owned 8,349 shares of the biopharmaceutical company’s stock after acquiring an additional 2,415 shares during the quarter. IFM Investors Pty Ltd’s holdings in Regeneron Pharmaceuticals were worth $2,316,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Accurate Investment Solutions Inc. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $31,000. HM Payson & Co. bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $31,000. Bridger Capital Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $30,000. Coastal Capital Group Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $38,000. Finally, Focused Wealth Management Inc raised its stake in shares of Regeneron Pharmaceuticals by 1,333.3% during the 2nd quarter. Focused Wealth Management Inc now owns 129 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 66.56% of the company’s stock.

REGN stock traded up $10.96 during trading hours on Friday, hitting $337.35. 18,055 shares of the stock were exchanged, compared to its average volume of 765,802. The company has a current ratio of 2.91, a quick ratio of 3.11 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $36.53 billion, a P/E ratio of 16.95, a P/E/G ratio of 1.46 and a beta of 1.14. The company has a 50-day simple moving average of $297.66 and a two-hundred day simple moving average of $304.26. Regeneron Pharmaceuticals Inc has a 12 month low of $271.37 and a 12 month high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share for the quarter, topping the consensus estimate of $5.13 by $1.54. The firm had revenue of $2.05 billion for the quarter, compared to analysts’ expectations of $1.98 billion. Regeneron Pharmaceuticals had a return on equity of 24.85% and a net margin of 28.13%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the business earned $5.87 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals Inc will post 18.91 earnings per share for the current year.

Regeneron Pharmaceuticals declared that its board has authorized a stock repurchase program on Tuesday, November 5th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the biopharmaceutical company to reacquire up to 2.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

A number of equities research analysts have recently issued reports on REGN shares. Oppenheimer dropped their price objective on Regeneron Pharmaceuticals from $480.00 to $430.00 in a research note on Wednesday. BidaskClub upgraded Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $344.00 to $358.00 and gave the stock a “market perform” rating in a research note on Wednesday. Piper Jaffray Companies set a $435.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, October 8th. Finally, Robert W. Baird upgraded Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $410.00 price objective on the stock in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $392.06.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. 11.84% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Operating Income

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.